Stablepharma Ltd
Stablepharma is dedicated to revolutionizing vaccine storage and distribution through its innovative StablevaX™ technology, which produces fridge-free vaccines that do not require refrigeration, thereby reducing vaccine wastage, costs, and environmental impact. The company aims to make vaccines accessible worldwide, especially in regions lacking cold chain infrastructure, and is actively developing and commercializing thermostable vaccines for diseases such as Tetanus and Diphtheria. With strategic partnerships, a strong research and development team, and a mission to eliminate the cold chain, Stablepharma is positioned as a leader in vaccine innovation and global health improvement.
Industries
Nr. of Employees
small (1-50)
Stablepharma Ltd
Patents
Products
Fridge‑free thermally stabilised tetanus–diphtheria vaccine in pre-filled syringe (lead candidate)
A reformulated Tetanus–Diphtheria booster candidate presented as a pre-dosed, dried vaccine in a pre-filled syringe that is reconstituted at administration and shown in preclinical studies to retain potency after elevated-temperature storage.
Fridge‑free thermally stabilised tetanus–diphtheria vaccine in pre-filled syringe (lead candidate)
A reformulated Tetanus–Diphtheria booster candidate presented as a pre-dosed, dried vaccine in a pre-filled syringe that is reconstituted at administration and shown in preclinical studies to retain potency after elevated-temperature storage.
Services
Collaborative reformulation of approved vaccines to develop thermostable, fridge‑free formats suitable for pre-filled syringe delivery; delivered through partnerships with vaccine manufacturers and academic groups.
Provision of preclinical study design support, potency and ELISA testing, and accelerated stability studies executed with partners to demonstrate thermostability and retained potency.
Collaborative reformulation of approved vaccines to develop thermostable, fridge‑free formats suitable for pre-filled syringe delivery; delivered through partnerships with vaccine manufacturers and academic groups.
Provision of preclinical study design support, potency and ELISA testing, and accelerated stability studies executed with partners to demonstrate thermostability and retained potency.
Expertise Areas
- Vaccine thermostabilisation
- Formulation and pre-filled delivery systems
- mRNA and LNP stabilization
- Preclinical and animal challenge studies
Key Technologies
- Trehalose-based dry stabilisation (sugar glass)
- Sponge-in-syringe drying and reconstitution
- Pre-filled pre-dosed syringe delivery
- mRNA drying and thermal stabilisation
News & Updates
Stablepharma is collaborating with BB-NCIPD to develop a thermally stable version of the Td vaccine using StablevaX™ technology.
Stablepharma was awarded the highly competitive and prestigious EIC Accelerator Grant of €2.5m.
Stablepharma is collaborating with BB-NCIPD to develop a thermally stable version of the Td vaccine using StablevaX™ technology.
Stablepharma was awarded the highly competitive and prestigious EIC Accelerator Grant of €2.5m.